SKYE insider trading
HealthcareSkye Bioscience, Inc.: insider trade history from SEC Form 4 filings.
About Skye Bioscience, Inc.
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Company website: skyebioscience.com
SKYE insider activity at a glance
FilingIQ tracks 98 insider transactions for SKYE in filings since Dec 16, 2021. The most recent transaction is dated Sep 23, 2026.
Across the full history, 4 open-market purchases
and 60 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on SKYE insider trades is 50.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest SKYE Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for SKYE?
- FilingIQ tracks 98 Form 4 insider transactions for SKYE (Skye Bioscience, Inc.), covering filings from Dec 16, 2021 onwards. 31 of those are dated within the last 90 days.
- Are SKYE insiders net buyers or net sellers?
- Across the full Form 4 history for SKYE, 4 transactions (4%) were open-market purchases and 60 (61%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does SKYE insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is SKYE in?
- Skye Bioscience, Inc. (SKYE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $22.99M.
Methodology & sources
Every SKYE insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.